Tag: hemoglobin A1C

1. Across 3 international registries, 5 similar patterns of hemoglobin A1c (HbA1c) were identified: low stable, intermediate stable, high stable, target increase, and high increase. 2. Older adolescents at time of diagnosis and minorities were more likely to experience poor glycemic control. Evidence Rating Level: 2 (Good) Study Rundown: The importance of good...
1. Tirzepatide was superior to placebo with regard to changes in HbA1c, serum glucose, body weight loss, and proportion of patients achieving HbA1c targets of less than 7.0%. 2. Compared to placebo, the proportion of adverse events with tirzepatide were mildly elevated. Evidence Rating Level: 1 (Excellent) Study Rundown: In many patients...
1. Among adults with poorly controlled type 2 diabetes treated with basal insulin without prandial insulin, continuous glucose monitoring resulted in significantly lower hemoglobin A1c levels at 8 months when compared with conventional blood glucose meter monitoring. 2. Patients using continuous glucose monitoring also had significantly improved secondary outcomes including...
1. The closed-loop system maintained glucose levels within the target range for a significantly greater percentage of time for children with type 1 diabetes. 2. More adverse events were reported with use of the closed-loop system. Evidence Rating Level: 1 (Excellent) Study Rundown: The target glycated hemoglobin level is difficult to maintain...
1. In this randomized controlled trial, patients with type 1 diabetes who used a closed-loop system spent a greater percentage of time in a target glycemic range compared to those who used a sensor-augmented insulin pump. 2. The closed-loop system was effective in reducing glycated hemoglobin level as well as...
Intensive glycemic control has been shown to reduce the risk of retinopathy and nephropathy in the setting of type 1 diabetes. While prior studies have established that an elevated hemoglobin A1C (HbA1C) is an independent risk factor for diabetic complications, few studies have followed patients from the time of...
1. In children with type 2 diabetes (T2DM) on metformin, those randomized to liraglutide had better glycemic control after 26 weeks compared to placebo treated patients. 2. Patients treated with liraglutide experienced more adverse events and gastrointestinal issues than placebo patients. Evidence Rating Level: 1 (Excellent)   Study Rundown: Incidence of both childhood...
1. Over a median period of almost 16 months, type 2 diabetic (T2DM) patients randomized to oral semaglutide for experienced a similar rate of cardiovascular (CV) events compared to placebo treated patients. 2. Discontinuation of therapy due to gastrointestinal issues occurred more often in the semaglutide group. Evidence Rating Level: 1...
1. In children with type 2 diabetes (T2DM) on metformin, those randomized to liraglutide had better glycemic control after 26 weeks compared to placebo treated patients. 2. Patients treated with liraglutide experienced more adverse events and gastrointestinal issues than placebo patients. Evidence Rating Level: 1 (Excellent)   Study Rundown: Incidence of both...
1. In a 15-year observational cohort study of type 2 diabetics treated with intensive compared to standard glucose control therapy the risk of major cardiovascular event or death was similar between both treatment groups. 2. There was no reported difference in health-related quality of life scores between the intensive and...